SCHEMBL35236

SCHEMBL35236

[c]1cccc2nc(-c3ccccc3)sc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.42
MAPT P10636 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 3/20 0.42
GLA P06280 3/20 0.42
GAA P10253 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 3/20 0.42
PKM P14618 2/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 6/20 0.42
NPC1 O15118 5/20 0.42
LMNA P02545 2/20 0.41
APP P05067 2/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10505563 0.86 KDM4E (0.56) KDM4EKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL9587476 0.85 KDM4E (0.41) KDM4EMAPTKMT2AALDH1A1GLA
SCHEMBL5543533 0.75 NOTUM (0.54) KDM4EMAPTKMT2AALDH1A1GLA
SCHEMBL5548200 0.74 ATP4A (0.54) KDM4EMAPTALDH1A1SMN1; SMN2HPGD
SCHEMBL547703 0.74 DYRK1A (0.49) ALDH1A1APP
SCHEMBL5969912 0.73 PI4KA (0.37) KDM4EMAPTKMT2AALDH1A1GAA
SCHEMBL4750497 0.72 SMN1; SMN2 (0.38) KDM4EMAPTKMT2AALDH1A1GAA
SCHEMBL5540904 0.71 KDM4E (0.42) KDM4EMAPTKMT2AALDH1A1GLA
2-Phenylbenzo[D]Thiazole SCHEMBL94005 0.71 RAB9A (0.75) KDM4EMAPTKMT2AALDH1A1GLA
2-Phenylbenzo[D]Thiazole SCHEMBL30988131 0.71 RAB9A (0.75) KDM4EMAPTKMT2AALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938236-B2 Antiviral agents against HBV infection DREXEL UNIVERSITY (US) 2018-04-10 US claimed
US-12037328-B2 Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 PRAMANA PHARMACEUTICALS INC. (CA) 2024-07-16 US disclosed
EP-4380566-A1 METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS 4E Therapeutics, Inc. (US) 2024-06-12 EP disclosed
CN-118076354-A Methods of treating migraine with MNK inhibitors 4E治疗公司 2024-05-24 CN disclosed
US-20240158357-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. (US) 2024-05-16 US disclosed
US-20240158379-A1 NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. 2024-05-16 US disclosed
US-20240148722-A1 SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS FOX CHASE CHEMICAL DIVERSITY CENTER INC. 2024-05-09 US disclosed
EP-4363419-A1 SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE 4E Therapeutics, Inc. (US) 2024-05-08 EP disclosed
CN-117980305-A Spirocyclic pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof 4E治疗公司 2024-05-03 CN disclosed
US-20240131004-A1 FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF INFLAMMATION AND PAIN KANNALIFE SCIENCES, INC. 2024-04-25 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060178350-A1 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes UNIVERSITEIT GENT (BE) 2006-08-10 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
US-5068325-A Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics KARL THOMAE GMBH (DE) 1991-11-26 US disclosed
EP-0200915-B1 AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Roche Diagnostics GmbH (DE) 1989-09-27 EP disclosed
US-4863949-A CARDIOVASCULAR DISORDER TREATMENT BOEHRINGER MANNHEIM GMBH (DE) 1989-09-05 US disclosed
EP-0280951-A1 Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates Roche Diagnostics GmbH (DE) 1988-09-07 EP disclosed
EP-0200915-A1 Aminopropanol derivatives, process for their preparation, their use and medicines containing them Roche Diagnostics GmbH (DE) 1986-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148722-A1 SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS TARDBP, FUS, HSPE1 KDM4E 2340/4885MAPT 7/4885KMT2A 3504/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885MAPT 4117/4885KMT2A 4267/4885
US-20060178350-A1 7-(2-Cyclohexylidene-ethylidene)-spiro[4.5]decanes NR3C2, PKD2, REN KDM4E 1012/4885MAPT 4256/4885KMT2A 3114/4885
US-20240131004-A1 FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF INFLAMMATION AND PAIN BAX, IL1B, BCL2A1 KDM4E 4357/4885MAPT 1370/4885KMT2A 4461/4885
US-20240158357-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE MAPT, PSEN1, APP KDM4E 3341/4885MAPT 1/4885KMT2A 3377/4885
US-12037328-B2 Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 GPR119, GPR3, GPR39 KDM4E 2650/4885MAPT 4178/4885KMT2A 3078/4885
US-20240158379-A1 NOVEL BENZOFURAN, BENZOTHIOPHENE, AND INDOLE ANALOGS THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE MAPT, HTT, APP KDM4E 1602/4885MAPT 1/4885KMT2A 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.